BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schmidt T, Alldinger I, Blank S, Klose J, Springfeld C, Dreikhausen L, Weichert W, Grenacher L, Bruckner T, Lordick F, Ulrich A, Büchler M, Ott K. Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection. European Journal of Surgical Oncology (EJSO) 2015;41:1340-7. [DOI: 10.1016/j.ejso.2015.05.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Blank S, Nienhüser H, Dreikhausen L, Sisic L, Heger U, Ott K, Schmidt T. Inflammatory cytokines are associated with response and prognosis in patients with esophageal cancer. Oncotarget 2017;8:47518-32. [PMID: 28537901 DOI: 10.18632/oncotarget.17671] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
2 Yang LP, Wang ZX, He MM, Wu HX, Yuan SQ, Wang W, Jin Y, Ren C, Wang ZQ, Wang FH, Li YH, Wang F, Xu RH. A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients. Cancer Manag Res 2019;11:3993-4003. [PMID: 31118812 DOI: 10.2147/CMAR.S197052] [Reference Citation Analysis]
3 Kroese TE, van Laarhoven HWM, Nilsson M, Lordick F, Guckenberger M, Ruurda JP, D'Ugo D, Haustermans K, van Cutsem E, van Hillegersberg R, van Rossum PSN. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. Eur J Cancer 2022;166:254-69. [PMID: 35339868 DOI: 10.1016/j.ejca.2022.02.018] [Reference Citation Analysis]
4 Blank S, Schmidt T, Heger P, Strowitzki MJ, Sisic L, Heger U, Nienhueser H, Haag GM, Bruckner T, Mihaljevic AL, Ott K, Büchler MW, Ulrich A. Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach? Gastric Cancer 2018;21:303-14. [DOI: 10.1007/s10120-017-0746-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
5 Sisic L, Strowitzki MJ, Blank S, Nienhueser H, Dorr S, Haag GM, Jäger D, Ott K, Büchler MW, Ulrich A, Schmidt T. Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis. Gastric Cancer 2018;21:552-68. [DOI: 10.1007/s10120-017-0751-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
6 Schmidt T, Mönig SP. [Therapeutic approach in oligometastatic gastric and esophageal cancer]. Chirurg 2017;88:1024-32. [PMID: 29098307 DOI: 10.1007/s00104-017-0548-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
7 Deng W, Yang Z, Dong X, Yu R, Wang W. Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities. Cancer Med 2021;10:659-74. [PMID: 33314798 DOI: 10.1002/cam4.3651] [Reference Citation Analysis]
8 Schizas D, Mylonas KS, Kapsampelis P, Bagias G, Katsaros I, Frountzas M, Hemmati P, Liakakos T. Patients undergoing surgery for oligometastatic oesophageal cancer survive for more than 2 years: bootstrapping systematic review data. Interactive CardioVascular and Thoracic Surgery 2020;31:299-304. [DOI: 10.1093/icvts/ivaa116] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Jung MK, Ott K, Chevallay M, Mönig SP. [Treatment options for oligometastatic gastric cancer]. Chirurg 2021;92:515-21. [PMID: 33544151 DOI: 10.1007/s00104-021-01353-5] [Reference Citation Analysis]
10 D'ugo D, Cananzi FCM, Persiani R, Agnes A, Biondi A. REGATTA trial: a call for the USA and Europe. The Lancet Oncology 2016;17:261-2. [DOI: 10.1016/s1470-2045(15)00619-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
11 Wu SG, He ZY, Wang Y, Sun JY, Lin HX, Su GQ, Li Q. Lymph node dissection improved survival in patients with metastatic thoracic esophageal cancer: An analysis of 220 patients from the SEER database. Int J Surg 2016;35:13-8. [PMID: 27613123 DOI: 10.1016/j.ijsu.2016.09.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
12 Shen J, Cao B, Wang Y, Xiao A, Qin J, Wu J, Yan Q, Hu Y, Yang C, Cao Z, Hu J, Yin P, Xie D, Gong J. Prospective randomized controlled trial to compare laparoscopic distal gastrectomy (D2 lymphadenectomy plus complete mesogastrium excision, D2 + CME) with conventional D2 lymphadenectomy for locally advanced gastric adenocarcinoma: study protocol for a randomized controlled trial. Trials 2018;19:432. [PMID: 30092843 DOI: 10.1186/s13063-018-2790-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
13 Beckert S, Königsrainer A. Oligometastasierung beim Magen- und Ösophaguskarzinom: Aktuelle Studienlage und chirurgische Konzepte. Chirurg 2018;89:505-9. [DOI: 10.1007/s00104-018-0645-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
14 Hu HM, Tsai HJ, Ku HY, Lo SS, Shan YS, Chang HC, Chao Y, Chen JS, Chen SC, Chiang CJ, Li AF, Wang HP, Wang TE, Bai LY, Wu MS, Chen LT, Liu TW, Yang YH. Survival outcomes of management in metastatic gastric adenocarcinoma patients. Sci Rep 2021;11:23142. [PMID: 34848751 DOI: 10.1038/s41598-021-02391-z] [Reference Citation Analysis]
15 Li Q, Xu X, Su D, Zhou T, Wang G, Li Z. Long-term survival of an elderly patient with advanced gastric cancer after combination therapy: a case report and literature review. BMC Cancer 2019;19:459. [PMID: 31096933 DOI: 10.1186/s12885-019-5683-4] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Chang X, Wu H, Li H, Li H, Zheng Y. PADI4 promotes epithelial-mesenchymal transition(EMT) in gastric cancer via the upregulation of interleukin 8. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02097-0] [Reference Citation Analysis]
17 Ceniceros L, Chopitea A, Pardo F, Rotellar F, Arbea L, Sola JJ, Subtil JC, Sangro B, Benito A, Hernández-Lizoain JL, Rodríguez J. Intensified neoadjuvant multimodal approach in synchronous liver metastases from gastric cancer: a single institutional experience. Clin Transl Oncol 2018;20:658-65. [PMID: 29043568 DOI: 10.1007/s12094-017-1767-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
18 Rogers MP, DeSantis AJ, DuCoin CG. Oligometastatic Adenocarcinoma of the Esophagus: Current Understanding, Diagnosis, and Therapeutic Strategies. Cancers (Basel) 2021;13:4352. [PMID: 34503162 DOI: 10.3390/cancers13174352] [Reference Citation Analysis]
19 Chen Z, Zhou Z, Hu Z, Xu Q, Wang J. Effect of FOLFOX4 combined with Brucea javanica emulsion on VEGF in patients with gastric cancer. Oncol Lett 2018;15:1079-83. [PMID: 29399168 DOI: 10.3892/ol.2017.7429] [Reference Citation Analysis]
20 Yang LP, Wang ZX, He MM, Jin Y, Ren C, Wang ZQ, Wang FH, Li YH, Wang F, Xu RH. The survival benefit of palliative gastrectomy and/or metastasectomy in gastric cancer patients with synchronous metastasis: a population-based study using propensity score matching and coarsened exact matching. J Cancer 2019;10:602-10. [PMID: 30719157 DOI: 10.7150/jca.28842] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
21 Helminen O, Mrena J, Sihvo E. Can We Increase the Resection Rate by Minimally Invasive Approach? Experience from 100 Minimally Invasive Esophagectomies. J Oncol 2019;2019:3809383. [PMID: 30915119 DOI: 10.1155/2019/3809383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Jung JO, Nienhüser H, Schleussner N, Schmidt T. Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach. Int J Mol Sci 2020;21:E951. [PMID: 32023907 DOI: 10.3390/ijms21030951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
23 Helminen O, Kytö V, Kauppila JH, Gunn J, Lagergren J, Sihvo E. Population-based study of anastomotic stricture rates after minimally invasive and open oesophagectomy for cancer. BJS Open 2019;3:634-40. [PMID: 31592081 DOI: 10.1002/bjs5.50176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
24 Procopio F, Marano S, Gentile D, Da Roit A, Basato S, Riva P, De Vita F, Torzilli G, Castoro C. Management of Liver Oligometastatic Esophageal Cancer: Overview and Critical Analysis of the Different Loco-Regional Treatments. Cancers (Basel) 2019;12:E20. [PMID: 31861604 DOI: 10.3390/cancers12010020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]